Ephrin Receptors (Eph): EphA1, EphA5, and EphA7 Expression in Uveal Melanoma-Associations with Clinical Parameters and Patient Survival.

Eph ephrin receptor melanoma uveal melanoma

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
30 Sep 2020
Historique:
received: 07 09 2020
revised: 27 09 2020
accepted: 28 09 2020
entrez: 3 10 2020
pubmed: 4 10 2020
medline: 4 10 2020
Statut: epublish

Résumé

Uveal melanoma is the most common primary intraocular malignancy in adults. The development of distant metastases is associated with a poor prognosis. Ephrine receptors (Eph) are the largest subpopulation of tyrosine kinase receptors. They play an important role in processes related to the formation and progression of cancer. The aim of the study was to evaluate the expression of ephrin receptors EphA1, EphA5, and EphA7 in uveal melanoma and its associations with clinicopathological parameters, overall survival, and disease-free survival. The study included 94 previously untreated patients who underwent enucleation due to uveal melanoma. High expression of EphA1 was positively correlated with a smaller tumor size, less frequent extra-scleral extension, lower mitotic activity, and more frequent vitreous hemorrhage. High expression of EphA5 was associated with less frequent chromosome 3 loss, absence of distant metastases, and more frequent vitreous hemorrhage. High expression of EphA7 was associated with a more frequent primary tumor location in the posterior pole. High EphA5 expression was associated with longer overall survival time. The above findings indicate that high expression of EphA1 and EphA5 can be considered a beneficial prognostic factor in uveal melanoma.

Identifiants

pubmed: 33007931
pii: life10100225
doi: 10.3390/life10100225
pmc: PMC7601896
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):2024-36
pubmed: 17673999
Ann Surg Oncol. 2015 Jul;22(7):2329-35
pubmed: 25391265
Hum Pathol. 2007 Nov;38(11):1649-56
pubmed: 17669470
Shanghai Kou Qiang Yi Xue. 2014 Oct;23(5):575-9
pubmed: 25543601
Drug Discov Today. 2014 May;19(5):661-9
pubmed: 24291785
Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33
pubmed: 15561600
Pathol Oncol Res. 2014 Apr;20(2):277-84
pubmed: 24022400
Annu Rev Pharmacol Toxicol. 2015;55:465-87
pubmed: 25292427
Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75
pubmed: 15928710
BMC Cancer. 2015 Jan 22;15:18
pubmed: 25609195
Klin Monbl Augenheilkd. 2016 Mar;232(3):290-7
pubmed: 26854480
Anticancer Res. 2018 Jun;38(6):3273-3282
pubmed: 29848674
Cell. 2011 Oct 28;147(3):554-64
pubmed: 22036564
Cell. 2008 Apr 4;133(1):38-52
pubmed: 18394988
Pathol Oncol Res. 2010 Jun;16(2):267-76
pubmed: 19949912
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
J Med Chem. 2012 Mar 8;55(5):2427-36
pubmed: 22329578
Mod Pathol. 2009 Jan;22(1):151-60
pubmed: 19011600
J Cancer Res Clin Oncol. 2010 Apr;136(4):595-601
pubmed: 19834740
Int J Exp Pathol. 2017 Feb;98(1):34-39
pubmed: 28421649
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
BMC Clin Pathol. 2014 Feb 04;14(1):8
pubmed: 24495444
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
Acta Histochem Cytochem. 2015 Jun 29;48(3):75-81
pubmed: 26160986
J Ovarian Res. 2016 Nov 25;9(1):83
pubmed: 27887627
Zhonghua Yan Ke Za Zhi. 2012 Nov;48(11):985-90
pubmed: 23302271
Curr Opin Cell Biol. 2007 Oct;19(5):534-42
pubmed: 17928214
Dev Dyn. 2007 Dec;236(12):3283-96
pubmed: 17557303
Oncogene. 2005 Aug 25;24(36):5637-47
pubmed: 16007213
APMIS. 2013 Jan;121(1):30-7
pubmed: 23030051
Oncogene. 2002 Oct 10;21(46):7011-26
pubmed: 12370823
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Anticancer Res. 2018 Mar;38(3):1685-1693
pubmed: 29491103
Int J Clin Exp Pathol. 2015 Jun 01;8(6):6821-7
pubmed: 26261568
Cell Mol Life Sci. 2012 Jun;69(11):1813-42
pubmed: 22204021
BMC Cancer. 2008 Mar 25;8:79
pubmed: 18366728

Auteurs

Malgorzata Gajdzis (M)

Department of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Stamatios Theocharis (S)

First Department of Pathology, National and Kapodistrian University of Athens, 15772 Athens, Greece.
Department of Pathology, Curie Institute, 75005 Paris, France.

Pawel Gajdzis (P)

Department of Pathology, Curie Institute, 75005 Paris, France.
Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Nathalie Cassoux (N)

Department of Ophthalmology, Institut Curie, 75005 Paris, France.

Sophie Gardrat (S)

Department of Biopathology, Institut Curie, PSL Research University, 75005 Paris, France.

Piotr Donizy (P)

Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Jerzy Klijanienko (J)

Department of Pathology, Curie Institute, 75005 Paris, France.

Radoslaw Kaczmarek (R)

Department of Ophthalmology, Wroclaw Medical University, 50-556 Wroclaw, Poland.

Classifications MeSH